Takaaki Terahara, PhD

  • 2Articles
  • 12.9KReads
  • 2020–2022Active
  • 10Collaborators
  • 26Citations

About

Takaaki Terahara, PhD is affiliated with Hisamitsu Pharmaceutical Co, Inc., Chiyoda-ku, Tokyo, Japan. Takaaki Terahara has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2020 and 2022. Their work focuses on Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

Transdermal HP-3070 for Hostility in Schizophrenia

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Original Research

Asenapine Transdermal System for Schizophrenia

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe